




(FIG. 1.A)




FIG. 1.B




FIG. 2




FIG. 3




FIG. 4

Pilot PK Study

Simulation and Comparison of Plasma Profiles of Reference Versus Three
Eurand Test Formulations




FIG. 5




FIG. 6




FIG. 7




FIG. 8






FIG. 9



Dissolution: USP Apparatus 2 (Paddles at 50 RPM (700 mL of 0.1N HCl for first 2 hrs followed by testing at pH 6.8 by adding 200 mL of modified buffer

FIG. 10



T1: PF391EA001 (8 mg IR + 12 mg TPR with t_{8h} of 8 hrs)
 T2: PF392EA001 (8 mg IR + 16 mg TPR with t_{8h} of 8 hrs)
 T3: PF379EA001 (8 mg IR + 16 mg TPR with t_{8h} of 12 hrs)
 Reference: Zofran 8 mg (BID 8 hrs apart)

FIG. 11